BCMA CAR-T cells

BIOLOGICAL5 trials

Conditions

Multiple MyelomaMultiple Myeloma in RelapseNeoplasm, Plasma CellNew Diagnosis TumorRefractory Multiple MyelomaRelapse Multiple MyelomaRelapsed and Refractory Multiple Myeloma

Early Phase 1

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma

NCT03661554

The Pregene (ShenZhen) Biotechnology Company, Ltd.Relapsed and Refractory Multiple Myeloma

Start: 2018-04-10End: 2018-11-30Target: 15Updated: 2018-09-10

Phase 1

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

NCT04272151

Chongqing Precision Biotech Co., LtdMultiple Myeloma, Multiple Myeloma in Relapse, Neoplasm, Plasma Cell

Start: 2019-12-01End: 2024-07-01Target: 40Updated: 2023-04-18

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

RecruitingNCT04271644

Chongqing Precision Biotech Co., LtdMultiple Myeloma, Multiple Myeloma in Relapse, Neoplasm, Plasma Cell

Start: 2019-04-01End: 2027-07-01Target: 80Updated: 2025-02-25

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

NCT05150522

Shenzhen University General HospitalMultiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma

Start: 2021-07-01End: 2024-07-31Target: 10Updated: 2021-12-09

Phase 2

A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

NCT05712083

Zhejiang UniversityMultiple Myeloma, New Diagnosis Tumor

Start: 2023-01-30End: 2024-04-01Target: 40Updated: 2023-02-21

Related Papers

The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain.

Journal of Clinical Oncology2021-05-209 citations

The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.